PharmaTher Holdings (OTCQB: PHRM) says President Trump’s April 18 executive order, could materially improve the policy environment for innovative ketamine‑based therapies. The order instructs HHS, FDA,…
The Presidential Executive order signed Saturday, directs federal health and drug agencies to accelerate research and review of psychedelic therapies for serious mental illness, with…
April 16, 2026
Half of GLP-1 Patients Stop Taking Their Medication. Here Is What That Means for Lexaria.
GLP-1 drugs have become one of the biggest success stories in pharmaceuticals. In 2025, the top seven branded products generated more than $73 billion in…
Shares of Psyence Biomedical Ltd. (Nasdaq: PBM) are popping, up 88% recently trading around $2.80 after swinging between $2.79 and $2.89 in today’s session, a notable move for a name that usually trades…
Immutep Limited (NASDAQ: IMMP) is exploding higher today, with shares up about 89% to 0.5961 on massive volume of over 614 million shares, versus an average of about…
New digital community from Teva Teva Pharmaceuticals (NYSE: TEVA) has launched Home Ground Schizophrenia Community, an online hub designed to support people living with schizophrenia and their…
Invivyd Inc. (NASDAQ: IVVD) jumped roughly 25% after investors digested fresh progress on its late‑stage COVID‑19 prevention program for monoclonal antibody VYD2311. The move comes as…
Shares of GameSquare Holdings, Inc. (Nasdaq: GAME) are ripping higher, up about 56–60% in early trading as the esports and creator‑economy company spikes from roughly $0.25 to about $0.40 on heavy…
April 06, 2026
ImmunityBio Shares Rebound as Company Moves to Resolve FDA Warning on Anktiva Promotion
ImmunityBio Inc. (NASDAQ: IBRX) is bouncing back after previously sliding 20–27% on news that the FDA’s Office of Prescription Drug Promotion issued a warning letter over…
Shares of Biodexa Pharmaceuticals plc (Nasdaq: BDRX) are rallying, recently trading around $1.05, up roughly 70% on the day as heavy volume floods into this beaten‑down micro‑cap oncology name….
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) has dosed the first participant in Calliope, a randomized, double‑blind, placebo‑controlled Phase 2 trial of TP‑05 (lotilaner), an investigational oral tablet…
March 27, 2026
AstraZeneca’s IL‑33 Drug Delivers Big COPD Win
AstraZeneca’s (NYSE: AZN) tozorakimab just delivered Phase III COPD data that can move the needle on a major respiratory asset, showing clinically meaningful exacerbation reductions…